Help us: Donate
Follow us on:
Γ—

Menu

Back

The Maximon Longevity Prize 2023: 50,000 CHF (56,000 USD)

These funds went to innovative longevity research projects.

2023 Maximon Longevity Prize2023 Maximon Longevity Prize

Maximon, Europe’s first longevity company builder, is pleased to announce that applications for the Maximon Longevity Prize 2023 are now open. This prestigious prize is awarded to translational longevity research projects that demonstrate exceptional potential to extend human healthspan and lifespan.

Maximon rewards the three winners of the prize with 50,000 CHF (56,000 USD). In addition, Maximon’s ventures Biolytica and Avea are offering exclusive rewards to the prize recipient: a personalized longevity concierge program valued at 20,000 CHF and a one-year subscription for longevity supplements valued at 5,000 CHF, respectively.

The prize is open to any academic/non-profit scientist, innovator, student, or startup founder who has either published their breakthrough research, holds a patent, or is in very advanced stages of research. Applications for the Maximon Longevity Prize 2023 will be accepted until June 30th, 2023.

The projects will be evaluated by a panel of renowned experts in the field of longevity research based on their potential for translational impact. The jury includes Dr. Elisabeth Roider, MD, PhD, MBA, Chief Scientific & Medical Officer at Maximon, Nir Barzilai, Director, Einstein Institute for Aging Research at Albert Einstein College of Medicine, Aubrey de Grey, President and CSO at LEV Foundation, Prof. Dr. Collin Ewald, Assistant Professor at ETH Zurich, Prof. Dr. Evelyne Yehudit Bischof, Associate Professor at Shanghai University of Medicine and Health Sciences, Prof Andrea Maier, MD PhD FRACP, Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, Yong Loo Lin School of Medicine, National University of Singapore, Heike Bischoff – Ferrari, Professor of Geriatrics and Aging Research at UZH, Sebastien Thuault, Chief Editor at Nature Aging, James Raaff, Co-Founder and Chief Program Officer at Biolytica AG, and Sophie Chabloz, Co-Founder & CPO at Avea Life.

The winners will be honoured during the Longevity Investors Conference (LIC), which brings together leading scientists and investors, fostering collaboration and innovation in the field of longevity. The conference will take place on September 27-29th at Le Grand Bellevue Hotel in Gstaad, Switzerland.

The Maximon Longevity Prize 2023 is a unique opportunity for researchers to showcase their work and contribute to the advancement of longevity research. Interested applicants are encouraged to submit their applications via the following link: https://www.maximon.com/longevityprize2023

About Maximon

Maximon empowers entrepreneurs to build impactful, science-based and scalable companies providing healthy aging and rejuvenation solutions. As a company builder, Maximon identifies the most promising business opportunities in the field of longevity and builds companies from scratch. Maximon provides proven structures, financing, and a unique and inspiring playground for entrepreneurs to build a longevity venture.

Contacts

Dr. Elisabeth Roider, Chief Scientific & Medical Officer at Maximon

Email: [email protected] Phone: +41 76 587 27 21

Maximon AG

Bahnhofplatz

CH-6300 Zug

Switzerland

www.maximon.com

Find us on Twitter LinkedIn Instagram Facebook

CategoryPress Releases
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.